Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Neurotrope (NTRP) Stock Price

News headlines about Neurotrope (NASDAQ:NTRP) have trended somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Neurotrope earned a media sentiment score of 0.22 on Accern’s scale. Accern also assigned news articles about the company an impact score of 47.9292219510528 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Shares of Neurotrope (NASDAQ NTRP) traded up $0.23 during trading on Friday, hitting $6.98. The company had a trading volume of 20,671 shares, compared to its average volume of 52,771. Neurotrope has a 52 week low of $3.40 and a 52 week high of $29.00.

WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Neurotrope (NTRP) Stock Price” was first reported by Stock Observer and is the sole property of of Stock Observer. If you are reading this report on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this report can be read at https://www.thestockobserver.com/2018/01/14/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-neurotrope-ntrp-stock-price.html.

Neurotrope Company Profile

Neurotrope, Inc, formerly BlueFlash Communications, Inc, is a biopharmaceutical company with its product candidates in pre-clinical and clinical development. The Company is focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer’s disease (AD), which is in the clinical testing stage.

Receive News & Ratings for Neurotrope Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurotrope and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply